Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models

被引:1
|
作者
Schlieper-Scherf, Steffen [1 ]
Hebach, Nils [2 ,3 ,4 ]
Hausmann, David [2 ,3 ,4 ]
Azorin, Daniel D. [2 ,3 ,4 ]
Hoffmann, Dirk C. [2 ,3 ,4 ]
Horschitz, Sandra [5 ,6 ]
Maier, Elena [1 ]
Koch, Phillip [5 ,6 ]
Karreman, Matthia A. [2 ,3 ,4 ]
Etminan, Nima [1 ]
Ratliff, Miriam [1 ,2 ]
机构
[1] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, Mannheim, Germany
[2] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Clin Cooperat Unit Neurooncol, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Neurol Clin, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany
[6] Hector Inst Translat Brain Res HITBR gGmbH, Mannheim, Germany
关键词
Glioma; Cancer neuroscience; Tumor microtubes; Cancer cell network; TTFields; ELECTRIC-FIELD; CELLS; RADIOTHERAPY; CANCER;
D O I
10.1007/s11060-024-04786-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study investigates the biological effect of Tumor Treating Fields (TTFields) on key drivers of glioblastoma's malignancy-tumor microtube (TM) formation-and on the function and overall integrity of the tumor cell network.MethodUsing a two-dimensional monoculture GB cell network model (2DTM) of primary glioblastoma cell (GBC) cultures (S24, BG5 or T269), we evaluated the effects of TTFields on cell density, interconnectivity and structural integrity of the tumor network. We also analyzed calcium (Ca2+) transient dynamics and network morphology, validating findings in patient-derived tumoroids and brain tumor organoids.ResultsIn the 2DTM assay, TTFields reduced cell density by 85-88% and disrupted network interconnectivity, particularly in cells with multiple TMs. A "crooked TM" phenotype emerged in 5-6% of treated cells, rarely seen in controls. Ca2+ transients were significantly compromised, with global Ca2+ activity reduced by 51-83%, active and periodic cells by over 50%, and intercellular co-activity by 52% in S24, and almost completely in BG5 GBCs. The effects were more pronounced at 200 kHz compared to a 50 kHz TTFields. Similar reductions in Ca2+ activity were observed in patient-derived tumoroids. In brain tumor organoids, TTFields significantly reduced tumor cell proliferation and infiltration.ConclusionOur comprehensive study provides new insights into the multiple effects of Inovitro-modeled TTFields on glioma progression, morphology and network dynamics in vitro. Future in vivo studies to verify our in vitro findings may provide the basis for a deeper understanding and optimization of TTFields as a therapeutic modality in the treatment of GB.
引用
收藏
页码:139 / 151
页数:13
相关论文
共 50 条
  • [1] GLIOBLASTOMA CELLS FROM A PATIENT POST-TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARE SENSITIVE TO TTFIELDS IN VITRO
    Michelhaugh, Sharon K.
    Kiousis, Sam
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2017, 19 : 87 - 87
  • [2] Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma
    Khagi, Simon
    Kotecha, Rupesh
    Gatson, Na Tosha N.
    Jeyapalan, Suriya
    Abdullah, Huda Ismail
    Avgeropoulos, Nicholas G.
    Batzianouli, Eleni T.
    Giladi, Moshe
    Lustgarten, Leonardo
    Goldlust, Samuel A.
    ONCOLOGIST, 2024,
  • [3] INDUCTION OF ANTI-TUMOR IMMUNITY BY TUMOR TREATING FIELDS (TTFIELDS) IN GLIOBLASTOMA
    Chen, Dongjiang
    Le, Son
    Hutchinson, Tarun
    Jin, Dan
    Sebastian, Mathew
    Liu, Tianyi
    Ghinaseddin, Ashley
    Rahman, Maryam
    Tran, David
    NEURO-ONCOLOGY, 2021, 23 : 100 - 100
  • [4] Patient experience using Tumor Treating Fields (TTFields) therapy for glioblastoma
    Batzianouli, Eleni
    Finogenova, Ksenia
    Johnson, Healther
    Abdullah, Huda Ismail
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 46 - 46
  • [5] LONGTERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY
    Rulseh, Aaron
    Sroubek, Jan
    Klener, Jan
    Vymazal, Josef
    NEURO-ONCOLOGY, 2017, 19 : 202 - 203
  • [6] Longterm survival in glioblastoma patients after tumor treating fields (TTFields) therapy
    Rulseh, Aaron
    Sroubek, Jan
    Klener, Jan
    Vymazal, Josef
    CANCER RESEARCH, 2017, 77
  • [7] COMBINATION OF TUMOR TREATING FIELDS (TTFIELDS) AND RADIOCHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Avgoustidou, M.
    Mahlknecht, U.
    NEURO-ONCOLOGY, 2018, 20 : 235 - 235
  • [8] Tumor Treating Fields (TTFields) in combination with radiochemotherapy in patients with newly diagnosed glioblastoma
    Avgoustidou, M.
    Mahlknecht, U.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S59 - S59
  • [9] Concomitant application of temozolomide, Tumor Treating Fields (TTFields), and lomustine in glioblastoma cells in vitro indicates better efficacy
    Fishman, H.
    Monin, R.
    Dor-On, E.
    Haber, A.
    Ehrle, S.
    Giladi, M.
    Weinberg, U.
    Palti, Y.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S79 - S79
  • [10] Tumor treating fields (TTFields) induce cancer cell permeability in vitro
    Voloshin, Tali
    Porat, Yaara
    Kaynan, Noa
    Klein-Goldberg, Anat
    Paz, Rom
    Volodin, Alexandra
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2020, 80 (16)